UNSPSC 51422318: Melengestrol

This classification denotes a therapeutic progestin with the molecular formula C23H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, BX98J4T6JU chemically known as 17-hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione but generally known as melengestrol, which bears US NIH Compound Identifier 21848. European Medicines Agency schedules Melengestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08722MIG.

UNSPSC 51422318 Melengestrol is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity shows no alignment with the code's abstract description. The sole relevant opportunity identified is Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems — a public health procurement unrelated to melengestrol, a veterinary growth promoter. A secondary record, the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs, addresses pharmacy benefit and prescription-fulfillment strategy rather than melengestrol or any specific pharmaceutical product. The code shows little to no recent activity that matches its nominal scope.

Seminole County's IFB, posted June 30, 2026, with response due July 26, 2023, seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; bidders must include shipping and delivery costs, comply with E-Verify and drug-free workplace certification, and maintain workers' compensation and general liability insurance under a two-year initial term with one-year renewal option. The Texas HHS RFI, posted April 3, 2026, with response due the same day, explores vendor capacity for direct-to-manufacturer pharmacy prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, focused on negotiated net pricing and outcomes-based agreements for state employee and self-insured group health plans. Neither opportunity substantively addresses melengestrol procurement, and the code does not reflect active state and local demand for the product category it nominally describes.